Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Protein or biologic · Protein or protein analogue
Detailed molecular class: Truncated protein analogue
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Modified IGF-I signaling/binding properties; exact molecule must be confirmed.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance
Truncated IGF-I sold as an anabolic enhancer; modifications are not trivial.
Human evidence
No controlled human efficacy finding was verified for the exact catalog identity in this screen.
Preclinical evidence
Analytical detection and animal exposure study; not clinical efficacy.
Critical reading and limitations
An antidoping analytical study demonstrates detectability, not therapeutic efficacy or human safety.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human safety, contraindications and interactions are not adequately established for the catalog product. Missing reports are not evidence of safety.
No validated human regimen in this dossier; do not infer dosing from LR3 or mecasermin.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
IGF-DES · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID33587816
Mongongu C, Coudoré F, Domergue V, Ericsson M, Buisson C, Marchand A.
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026